Table 4.
Comparison by sex of the difference of active ingredients and cost during six months before the lockdown, the first six months and from six to twelve months after the lockdown
| 6 months before lockdown (n = 662,754) |
0–6 months after lockdown (N = 654,954) |
6–12 months after lockdown (N = 649,702) |
||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Men | Women | p-value | Total | Men | Women | p-value | Total | Men | Women | p-value | |
| People with prescribed medications, N | 380,774 | 163,080 | 217,694 | < 0.001 | 370,876 | 157,973 | 212,903 | < 0.001 | 364,300 | 154,920 | 209,380 | < 0.001 |
| No. of active ingredients, Mean ± SD | 2.64 ± 1.77 | 2.56 ± 1.80 |
2.52 ± 1.72 |
< 0.001 | 2.46 ± 1.61 |
2.37 ± 1.61 |
2.39 ± 1.57 |
< 0.001 | 2.17 ± 1.56 |
2.35 ± 1.31 |
2.38 ± 1.63 | < 0.001 |
|
Cost of active ingredients, Mean ± SD |
81.58 ± 124.25 | 91.70 ± 139.06 | 64.60 ± 102.88 | < 0.001 | 81.33 ± 123.33 | 91.67 ± 138.98 |
64.85 ± 103.11 |
< 0.001 | 67.46 ± 102.61 | 76.72 ± 115.76 | 54.46 ± 86.12 | < 0.001 |
No. Number; SD Standard deviation; Bold values indicate the results are statistically significant.